Breaking News Instant updates and real-time market news.

MRK

Merck

$59.43

-1.07 (-1.77%)

08:36
12/22/16
12/22
08:36
12/22/16
08:36

Merck announces Keytruda approval in Japan

As previously reported, Merck announced on December 19 that KEYTRUDA, the company's anti-PD-1 therapy, has been approved in Japan for the treatment of certain patients with PD-L1-positive unresectable advanced/recurrent non-small cell lung cancer in the first- and second-line treatment settings at a fixed dose of 200 mg every three weeks. MSD will manufacture and market KEYTRUDA in Japan and will promote it with Taiho Pharmaceutical Co., Ltd. The Japanese Ministry of Health, Labour, and Welfare approval is supported by findings from both the KEYNOTE-024 and KEYNOTE-010 studies. KEYNOTE-024 is a randomized, open-label, phase 3 study evaluating KEYTRUDA monotherapy at a fixed dose of 200 mg compared to standard of care platinum-containing chemotherapy for the treatment of patients with both squamous and non-squamous metastatic NSCLC. The study enrolled patients who had not received prior systemic chemotherapy treatment for their metastatic disease and whose tumors had high PD-L1 expression with no EGFR or ALK aberrations. KEYNOTE-010 is an open-label, randomized, phase 2/3 trial assessing two doses of KEYTRUDA compared to docetaxel, a standard of care chemotherapy. This study enrolled patients with any level of PD-L1 expression who had progressed following platinum-containing chemotherapy and, if appropriate, targeted therapy for EGFR or ALK genomic tumor aberrations.

  • 19

    Jan

  • 01

    Feb

  • 21

    Feb

  • 08

    Mar

MRK Merck
$59.43

-1.07 (-1.77%)

12/12/16
BMOC
12/12/16
NO CHANGE
BMOC
Merck Verubecestat ' highly under-appreciated,' says BMO Capital
After attending an Alzheimer's conference, BMO Capital analyst Alex Arfaei has "increased confidence" that Alzheimer's Disease is "at least initially caused by a buildup of amyloid beta in the brain." The analyst reports that "a few experts" were upbeat on the ability of Merck's BACE inhibitor, Verubecestat, to slow amyloid beta production. The analyst says that BACE inhibitors "are a potent way of slowing (amyloid beta) production, and if safe, could have great promise." He thinks that " Verubecestat is a highly under-appreciated asset," and keeps a $72 price target and an Outperform rating on the stock.
12/16/16
BARD
12/16/16
NO CHANGE
Target $100
BARD
Outperform
Gilead Hep C royalty to Merck looks increasingly likely, says Baird
After Merck (MRK) won its second Hep C patent infringement case against Gilead (GILD) this year and a jury awarded $2.54B in damages, Baird analyst Brian Skorney noted that Gilead plans to appeal but also said that a royalty looks increasingly likely. Skorney, who now assumes a 50% probability of the $2.54B payout and a 35% chance of a 10% royalty on Hep C sales in perpetuity, called the payout "chump change" for Gilead and said that a 10% royalty would provide a "modest drag" on Gilead's free cash. The analyst has an Outperform rating and $100 price target on Gilead shares.
12/19/16
JEFF
12/19/16
DOWNGRADE
Target $48
JEFF
Underperform
Merck downgraded to Underperform from Hold at Jefferies
Jefferies analyst Jeffrey Holford downgraded Merck (MRK) to Underperform, his firm's sell-rating equivalent. The analyst sees Pharmaceutical sector fundamentals weakening in 2017 amid political overhangs and an adverse macro environment. Potential dual eligible rebate reform is the most significant risk, Holford tells investors in a research note. Specific to Merck, the analyst expects further pressure on Keytruda in 2018, driven by share losses in non-small cell lung cancer to Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Roche (RHHBY). Merck screens poorly on many valuation metrics, Holford contends. He lowered his price target for the shares to $48 from $59. The stock closed Friday up 7c to $62.44. The analyst this morning also upgraded both Bristol-Myers Squibb (BMY) and Bayer (BAYRY) to Buy from Hold. His top picks in Pharmaceuticals are AbbVie (ABBV) and Eli Lilly (LLY) for the U.S. and AstraZeneca and Novartis (NVS) in Europe.
12/19/16
12/19/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Merck (MRK) downgraded to Underperform from Hold at Jefferies with analyst Jeffrey Holford saying he sees Pharmaceutical sector fundamentals weakening in 2017 amid political overhangs and an adverse macro environment. 2. Lowe's (LOW) downgraded to Neutral from Buy at Citi with analyst Kate McShane citing the potential for the company missing recently stated comp targets. 3. JAKKS Pacific (JAKK) was downgraded to Neutral from Overweight at Piper Jaffray and to Market Perform from Outperform at BMO Capital. 4. Sunoco (SUN) downgraded to Neutral from Buy at BofA/Merrill with analyst Gabe Moreen saying Moody's downgrade of Sunoco's debt to Ba2 to Ba3 reaffirms that its leverage is elevated and could continue to pressure its ability to deleverage near-term. 5. KeyCorp (KEY) downgraded to Equal Weight from Overweight at Stephens with analyst Terry McEvoy citing four total rate hikes occurring in the first and third quarter of 2017 and 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

CRVS

Corvus Pharmaceuticals

$13.00

1.13 (9.52%)

20:37
08/23/17
08/23
20:37
08/23/17
20:37
Upgrade
Corvus Pharmaceuticals rating change  »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$56.28

0.33 (0.59%)

20:35
08/23/17
08/23
20:35
08/23/17
20:35
Upgrade
Portola Pharmaceuticals rating change  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 02

    Feb

TEVA

Teva

$16.49

-0.52 (-3.06%)

20:35
08/23/17
08/23
20:35
08/23/17
20:35
Downgrade
Teva rating change  »

Teva downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 27

    Sep

LOW

Lowe's

$73.01

-2.81 (-3.71%)

20:33
08/23/17
08/23
20:33
08/23/17
20:33
Downgrade
Lowe's rating change  »

Lowe's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 21

    Nov

HRL

Hormel Foods

$33.92

-0.46 (-1.34%)

, DLTR

Dollar Tree

$74.32

-0.63 (-0.84%)

20:25
08/23/17
08/23
20:25
08/23/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

HRL

Hormel Foods

$33.92

-0.46 (-1.34%)

DLTR

Dollar Tree

$74.32

-0.63 (-0.84%)

SJM

J.M. Smucker

$118.85

-1.01 (-0.84%)

TIF

Tiffany

$88.72

0.22 (0.25%)

TTC

Toro Company

$69.02

-1.76 (-2.49%)

SPLS

Staples

$10.18

-0.02 (-0.20%)

BURL

Burlington Stores

$84.95

-1.43 (-1.66%)

MIK

Michaels

$19.61

0.02 (0.10%)

SIG

Signet Jewelers

$51.89

-0.26 (-0.50%)

ANF

Abercrombie & Fitch

$9.61

0.46 (5.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 05

    Sep

  • 06

    Sep

  • 03

    Oct

  • 04

    Oct

HSY

Hershey

$107.44

0.34 (0.32%)

19:16
08/23/17
08/23
19:16
08/23/17
19:16
Hot Stocks
Hershey Company to acquire 1.5M common shares from Hershey Trust »

The Hershey Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSADY

MS&AD Insurance

$17.08

-0.085 (-0.50%)

19:07
08/23/17
08/23
19:07
08/23/17
19:07
Hot Stocks
MS&AD Insurance to acquire First Capital Insurance in $1.6B deal »

Fairfax Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$169.00

-1.07 (-0.63%)

18:46
08/23/17
08/23
18:46
08/23/17
18:46
Hot Stocks
Amgen: Lancet Oncology publishes survival analysis from KYPROLIS Phase 3 trial »

Amgen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Sep

  • 11

    Sep

  • 14

    Sep

  • 02

    Dec

  • 03

    Feb

  • 17

    May

GE

General Electric

$24.39

-0.21 (-0.85%)

, ABB

ABB

$23.13

-0.01 (-0.04%)

18:39
08/23/17
08/23
18:39
08/23/17
18:39
Periodicals
GE resumes talks with ABB over industrial solutions deal, Reuters reports »

General Electric (GE) has…

GE

General Electric

$24.39

-0.21 (-0.85%)

ABB

ABB

$23.13

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 11

    Sep

  • 02

    Oct

LZB

La-Z-Boy

$24.95

-6.3 (-20.16%)

, AMZN

Amazon.com

$958.00

-8.9 (-0.92%)

18:17
08/23/17
08/23
18:17
08/23/17
18:17
Periodicals
La-Z-Boy in talks with Amazon over youth shopper outreach, MarketWatch reports »

La-Z-Boy (LZB) is in…

LZB

La-Z-Boy

$24.95

-6.3 (-20.16%)

AMZN

Amazon.com

$958.00

-8.9 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 29

    Aug

VLKAY

Volkswagen

$30.67

0.19 (0.62%)

18:14
08/23/17
08/23
18:14
08/23/17
18:14
Periodicals
VW to launch two-tone compact SUV, Bloomberg says »

Volkswagen plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$10.71

0.06 (0.56%)

18:01
08/23/17
08/23
18:01
08/23/17
18:01
Hot Stocks
Ford names Jason Luo as chairman, CEO of Ford China »

Ford announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$238.09

-1.66 (-0.69%)

, LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

17:47
08/23/17
08/23
17:47
08/23/17
17:47
Periodicals
Boeing 'disappointed' company not chosen for cruise missile deal, Bloomberg says »

Lockheed (LMT), Raytheon…

BA

Boeing

$238.09

-1.66 (-0.69%)

LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

RTN

Raytheon

$178.19

-1.03 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

HBM

Hudbay Minerals

$8.50

0.2 (2.41%)

17:44
08/23/17
08/23
17:44
08/23/17
17:44
Hot Stocks
Hudbay Minerals acquires 10.76M common shares of Mason Resources »

Hudbay Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

17:32
08/23/17
08/23
17:32
08/23/17
17:32
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees Q4 PC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

GES

Guess

$12.48

0.11 (0.89%)

, TLYS

Tilly's

$9.60

0.88 (10.09%)

17:29
08/23/17
08/23
17:29
08/23/17
17:29
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Guess…

GES

Guess

$12.48

0.11 (0.89%)

TLYS

Tilly's

$9.60

0.88 (10.09%)

WSM

Williams-Sonoma

$43.40

0.55 (1.28%)

PVH

PVH Corp.

$120.04

-0.28 (-0.23%)

YUME

YuMe

$5.15

0.09 (1.78%)

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

HEI

Heico

$81.11

-0.95 (-1.16%)

GBT

Global Blood Therapeutics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 24

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

  • 06

    Sep

  • 06

    Sep

  • 07

    Sep

  • 07

    Sep

  • 08

    Sep

  • 11

    Sep

  • 28

    Sep

MATX

Matson

$24.02

0.24 (1.01%)

17:28
08/23/17
08/23
17:28
08/23/17
17:28
Hot Stocks
Matson upgrading its Honolulu terminal »

Matson announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$33.90

0.78 (2.36%)

17:24
08/23/17
08/23
17:24
08/23/17
17:24
Syndicate
Breaking Syndicate news story on Tactile Systems »

Tactile Systems files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$33.90

0.78 (2.36%)

17:23
08/23/17
08/23
17:23
08/23/17
17:23
Syndicate
Breaking Syndicate news story on Tactile Systems »

Tactile Systems files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIVI

Civitas Solutions

$18.30

-0.1 (-0.54%)

17:21
08/23/17
08/23
17:21
08/23/17
17:21
Recommendations
Civitas Solutions analyst commentary  »

Civitas announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$179.28

-1.39 (-0.77%)

17:20
08/23/17
08/23
17:20
08/23/17
17:20
Hot Stocks
L3 Technologies awarded $172.9M government contract modification »

L-3 Communications Vertex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$238.08

-1.67 (-0.70%)

17:19
08/23/17
08/23
17:19
08/23/17
17:19
Hot Stocks
Boeing awarded $222.5M government contract modification »

The Boeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$178.19

-1.03 (-0.57%)

17:18
08/23/17
08/23
17:18
08/23/17
17:18
Hot Stocks
Raytheon awarded approximately $900M government contract »

Raytheon Co., Tucson,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

17:17
08/23/17
08/23
17:17
08/23/17
17:17
Hot Stocks
Lockheed Martin awarded approximately $900M government contract »

Lockheed Martin Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

, SSNLF

Samsung

$2,020.00

-10 (-0.49%)

17:11
08/23/17
08/23
17:11
08/23/17
17:11
Hot Stocks
HP Inc. sees Samsung deal closing in Q4 »

HP Inc. (HPQ) said it saw…

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

SSNLF

Samsung

$2,020.00

-10 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.